CUCCI, Marie Angele
CUCCI, Marie Angele
SCIENZE CLINICHE E BIOLOGICHE
A 4-year multicenter follow-up of neutralizing anti-interferon antibodies in ms patients treated with high dose (375 mcg) interferon beta-1b
2006-01-01 A. TAVELLA; A. RICCI; P. BARBERO; A. PIPIERI; A. CUCCI; B. FERRERO; A. ROVERA; G. CONTESSA; M. BERGUI; E. VERSINO; M. CLERICO; L. DURELLI; FOR THE OPTIMS TRIAL STUDY GROUP
A 4-year study of anti-interferon neutralizing antibodies in relapsing-remitting multiple sclerosis patients treated with different doses of interferon beta-1b
2006-01-01 A. RICCI; A. CUCCI; A. ROVERA; M. CLERICO; L. DURELLI; FOR THE OPTIMS TRIAL STUDY GROUP
A multicentre trial comparing two different doses of ifn beta-1b. the optimization of interferon for ms (optims) study.
2004-01-01 E. VERDUN; P. BARBERO; A. PIPIERI; A. RICCI; M. CLERICO; A. CUCCI; L. GIORDANO; L. DURELLI
Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months
2016-01-01 Durelli, L; De Mercanti, S; Rolla, S; Cucci, A; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Annovazzi, P; Horakova, D; Novelli, F; Clerico, M
Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation
2016-01-01 Durelli, L; De Mercanti, SF; Cucci, A; Taverna, D; Rolla, S; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Horakova, D; Annovazzi, P; Novelli, F; Clerico, M
Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials
2012-01-01 De Mercanti, S.; Cucci, A.; Viglietti,E.; Giai Via,A.; Taverna, D.; Cimino,D.;Rolla, S.; Bardina,V.; Novelli, F.; Vargas,J.; Gibbin,M.; Piazza,F.; Vladic,A.; Brina.V.; Habek,M.; Cocco,E.; Annavazzi,P.; Horakova,D.; Clerico, M.; Durelli, L.
Anti-interferon neutralising antibody occurrence in relapsing remitting ms patients treated with a ifn beta-1b dose higher than the standard one: long-term evaluation
2005-01-01 A. RICCI; P. BARBERO; A. PIPIERI; A. CUCCI; M. CLERICO; B. FERRERO; A. ROVERA; L. GIORDANO; G. CONTESSA; E. FESTA; L. DURELLI; ON BEHALF OF THE OPTIMS TRIAL STUDY GROUP
Anti-TR antibodies positive cerebellar syndrome as the presentation symptom of a case of Hodgkin’s disease (HD).
2003-01-01 M. CLERICO; E. ROTA; A. RICCI; E. VERDUN; P. BARBERO; A. PIPIERI; A. CUCCI; L. GIORDANO; L. DURELLI
Autoimmunity profile in interferon beta- 1a treated Multiple Sclerosis patients. the auprin study: comparison of 2 different dosage of subcutaneous interferon-beta 1a
2005-01-01 E. VERDUN; L. GIORDANO; M.A. CUCCI; A. RICCI; P. BARBERO; A. PIPIERI; M. CLERICO; G. AIMO; L. DURELLI; THE AUPRIN STUDY GROUP
Autoimmunity profile in interferon beta- 1a treated multiple sclerosis patients. the auprin study: comparision of 2 different dosage of subcutaneous interferon-beta 1a.
2004-01-01 E. VERDUN; A. RICCI; M.A. CUCCI; P. BARBERO; A. PIPIERI; M. CLERICO; L. GIORDANO; L. DELFICO; T. TASSINARI; L. MOTTI; M. PACIELLO; A. REGGIO; G. AIMO; L. DURELLI; ON BEHALF OF THE AUPRIN STUDY GROUP
Autoimmunity profile in interferon beta-1a treated Multiple Sclerosis patients. The AUPRIN Study: comparison of 2 different dosages of subcutaneous interferon beta-1a
2004-01-01 E. VERDUN; A. RICCI; M.A. CUCCI; P. BARBERO; A. PIPIERI; M. CLERICO; L. GIORDANO; L. DELFICO; G. AIMO; T. M. PACIELLO; T. TASSINARI; L. MOTTI; A. REGGIO; L. DURELLI; THE AUPRIN STUDY GROUP
Clinical and laboratory tolerability evaluation of treatment with high-dose interferon beta-1b (500mcg every-other-day, subcutaneously) in ms patients.
2003-01-01 A. PIPIERI; P. BARBERO; M. CLERICO; E. VERDUN; E. VERSINO; A. CUCCI; E. PUCCI; E. CARTECHINI; L. MANNESCHI; G. GIULIANI; E. MONTANARI; L. DURELLI
Evaluation of mitochondrial manganese in leukocyte of multiple sclerosis patients.
2003-01-01 M.A. CUCCI; A. NONNATO; P. BARBERO; L. BRANCIFORTE; A. RICCI; E. VERDUN; M. CLERICO; A. PIPIERI; A. CAROPRESO; G. PESCARMONA; L. DURELLI
Every-other-day interferon beta-1b compared with once weekly interferon beta 1-a in ms. further analysis of treatment effect on mri activity and neutralizing antibodies (nabs) in the INCOMIN trial
2004-01-01 P. BARBERO; M. BERGUI; A. RICCI; E. VERSINO; A. PIPIERI; E. VERDUN; M. CLERICO; L. GIORDANO; A. CUCCI; L. DURELLI; INCOMIN STUDY GROUP
High-dose interferon-beta-1b (500 mcg every-other-day, subcutaneously) treatment in MS patients. Long-term evaluation and longitudinal comparison with preceding treatment with lower IFN beta dose
2004-01-01 P. Barbera; A. Pipieri; E. Verdun; M. Clerico; A. Ricci; M. A. Cucci; L. Giordano; E. Cartechini; G. Giuliani; E. Montanari; M. Bergui; L. Durelli
How do Treg cell function and related cytokines levels change in alemtuzumab treated patients? A 24 months immunological study
2014-01-01 S De Mercanti ; M Clerico ; S Rolla ; V Bardina ; M.A Cucci ; D Taverna ; D Cimino ; F Piazza ; E Virgilio ; D Armocida ; M Basso ; A Vladic ; M Habek ; I Adamec ; V Brinar ; E Cocco ; J Frau ; P Annovazzi ; D Horàkovà ; I Kovàrovà ; F Novelli ; L Durelli
IFN beta-1b 500 mcg every-other-day, subcutaneously in MS patients. Tolerability, clinical and MRI results after one year of treatment
2005-01-01 M. Clerico; A. Pipaeri; P. Barbero; M. Bergui; F. Bruno; E. Verdun; L. Giordano; A. Ricci; E. Pucci; G. Giuliani; E. Cartechini; L. Manneschi; E. Montanari; E. Versino; A. Cucci; L. Durelli
IFN beta-1b in multiple sclerosis: comparing two different doses (the Optims Study).
2004-01-01 E. VERDUN; P. BARBERO; A. PIPIERI; A. RICCI; M. CLERICO; A. CUCCI; M. BERGUI; E. VERSINO; L. GIORDANO; M. ZAFFARONI; E. MONTANARI; G. GIULIANI; L. DURELLI; AND THE OPTIMS STUDY GROUP
Increasing dose of ifn beta 1b in ms patients: preliminary nab results from the optims study.
2003-01-01 VERDUN E; A. RICCI; P. BARBERO; M. CLERICO; A. PIPIERI; M. BERGUI; E. VERSINO; A. CUCCI; J.J. ZHONG; L. DURELLI; AND OPTIMS STUDY GROUP
Indicators of treatment response to interferon beta in ms. mxa protein, il-10 mrna or mri?
2006-01-01 G. CONTESSA; M. CLERICO; P. BARBERO; B. FERRERO; A. CUCCI; E. VERSINO; G. GIULIANI; E. MONTANARI; L. DURELLI; THE OPTIMS STUDY GROUP
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A 4-year multicenter follow-up of neutralizing anti-interferon antibodies in ms patients treated with high dose (375 mcg) interferon beta-1b | 2006 | A. TAVELLA; A. RICCI; P. BARBERO; A. PIPIERI; A. CUCCI; B. FERRERO; A. ROVERA; G. CONTESSA; M. BERGUI; E. VERSINO; M. CLERICO; L. DURELLI; FOR THE OPTIMS TRIAL STUDY GROUP | |
| A 4-year study of anti-interferon neutralizing antibodies in relapsing-remitting multiple sclerosis patients treated with different doses of interferon beta-1b | 2006 | A. RICCI; A. CUCCI; A. ROVERA; M. CLERICO; L. DURELLI; FOR THE OPTIMS TRIAL STUDY GROUP | |
| A multicentre trial comparing two different doses of ifn beta-1b. the optimization of interferon for ms (optims) study. | 2004 | E. VERDUN; P. BARBERO; A. PIPIERI; A. RICCI; M. CLERICO; A. CUCCI; L. GIORDANO; L. DURELLI | |
| Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months | 2016 | Durelli, L; De Mercanti, S; Rolla, S; Cucci, A; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Annovazzi, P; Horakova, D; Novelli, F; Clerico, M | |
| Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation | 2016 | Durelli, L; De Mercanti, SF; Cucci, A; Taverna, D; Rolla, S; Bardina, V; Cocco, E; Vladic, A; Soldo-Butkovic, S; Habek, M; Adamec, I; Horakova, D; Annovazzi, P; Novelli, F; Clerico, M | |
| Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials | 2012 | De Mercanti, S.; Cucci, A.; Viglietti,E.; Giai Via,A.; Taverna, D.; Cimino,D.;Rolla, S.; Bardina,V.; Novelli, F.; Vargas,J.; Gibbin,M.; Piazza,F.; Vladic,A.; Brina.V.; Habek,M.; Cocco,E.; Annavazzi,P.; Horakova,D.; Clerico, M.; Durelli, L. | |
| Anti-interferon neutralising antibody occurrence in relapsing remitting ms patients treated with a ifn beta-1b dose higher than the standard one: long-term evaluation | 2005 | A. RICCI; P. BARBERO; A. PIPIERI; A. CUCCI; M. CLERICO; B. FERRERO; A. ROVERA; L. GIORDANO; G. CONTESSA; E. FESTA; L. DURELLI; ON BEHALF OF THE OPTIMS TRIAL STUDY GROUP | |
| Anti-TR antibodies positive cerebellar syndrome as the presentation symptom of a case of Hodgkin’s disease (HD). | 2003 | M. CLERICO; E. ROTA; A. RICCI; E. VERDUN; P. BARBERO; A. PIPIERI; A. CUCCI; L. GIORDANO; L. DURELLI | |
| Autoimmunity profile in interferon beta- 1a treated Multiple Sclerosis patients. the auprin study: comparison of 2 different dosage of subcutaneous interferon-beta 1a | 2005 | E. VERDUN; L. GIORDANO; M.A. CUCCI; A. RICCI; P. BARBERO; A. PIPIERI; M. CLERICO; G. AIMO; L. DURELLI; THE AUPRIN STUDY GROUP | |
| Autoimmunity profile in interferon beta- 1a treated multiple sclerosis patients. the auprin study: comparision of 2 different dosage of subcutaneous interferon-beta 1a. | 2004 | E. VERDUN; A. RICCI; M.A. CUCCI; P. BARBERO; A. PIPIERI; M. CLERICO; L. GIORDANO; L. DELFICO; T. TASSINARI; L. MOTTI; M. PACIELLO; A. REGGIO; G. AIMO; L. DURELLI; ON BEHALF OF THE AUPRIN STUDY GROUP | |
| Autoimmunity profile in interferon beta-1a treated Multiple Sclerosis patients. The AUPRIN Study: comparison of 2 different dosages of subcutaneous interferon beta-1a | 2004 | E. VERDUN; A. RICCI; M.A. CUCCI; P. BARBERO; A. PIPIERI; M. CLERICO; L. GIORDANO; L. DELFICO; G. AIMO; T. M. PACIELLO; T. TASSINARI; L. MOTTI; A. REGGIO; L. DURELLI; THE AUPRIN STUDY GROUP | |
| Clinical and laboratory tolerability evaluation of treatment with high-dose interferon beta-1b (500mcg every-other-day, subcutaneously) in ms patients. | 2003 | A. PIPIERI; P. BARBERO; M. CLERICO; E. VERDUN; E. VERSINO; A. CUCCI; E. PUCCI; E. CARTECHINI; L. MANNESCHI; G. GIULIANI; E. MONTANARI; L. DURELLI | |
| Evaluation of mitochondrial manganese in leukocyte of multiple sclerosis patients. | 2003 | M.A. CUCCI; A. NONNATO; P. BARBERO; L. BRANCIFORTE; A. RICCI; E. VERDUN; M. CLERICO; A. PIPIERI; A. CAROPRESO; G. PESCARMONA; L. DURELLI | |
| Every-other-day interferon beta-1b compared with once weekly interferon beta 1-a in ms. further analysis of treatment effect on mri activity and neutralizing antibodies (nabs) in the INCOMIN trial | 2004 | P. BARBERO; M. BERGUI; A. RICCI; E. VERSINO; A. PIPIERI; E. VERDUN; M. CLERICO; L. GIORDANO; A. CUCCI; L. DURELLI; INCOMIN STUDY GROUP | |
| High-dose interferon-beta-1b (500 mcg every-other-day, subcutaneously) treatment in MS patients. Long-term evaluation and longitudinal comparison with preceding treatment with lower IFN beta dose | 2004 | P. Barbera; A. Pipieri; E. Verdun; M. Clerico; A. Ricci; M. A. Cucci; L. Giordano; E. Cartechini; G. Giuliani; E. Montanari; M. Bergui; L. Durelli | |
| How do Treg cell function and related cytokines levels change in alemtuzumab treated patients? A 24 months immunological study | 2014 | S De Mercanti ; M Clerico ; S Rolla ; V Bardina ; M.A Cucci ; D Taverna ; D Cimino ; F Piazza ; E Virgilio ; D Armocida ; M Basso ; A Vladic ; M Habek ; I Adamec ; V Brinar ; E Cocco ; J Frau ; P Annovazzi ; D Horàkovà ; I Kovàrovà ; F Novelli ; L Durelli | |
| IFN beta-1b 500 mcg every-other-day, subcutaneously in MS patients. Tolerability, clinical and MRI results after one year of treatment | 2005 | M. Clerico; A. Pipaeri; P. Barbero; M. Bergui; F. Bruno; E. Verdun; L. Giordano; A. Ricci; E. Pucci; G. Giuliani; E. Cartechini; L. Manneschi; E. Montanari; E. Versino; A. Cucci; L. Durelli | |
| IFN beta-1b in multiple sclerosis: comparing two different doses (the Optims Study). | 2004 | E. VERDUN; P. BARBERO; A. PIPIERI; A. RICCI; M. CLERICO; A. CUCCI; M. BERGUI; E. VERSINO; L. GIORDANO; M. ZAFFARONI; E. MONTANARI; G. GIULIANI; L. DURELLI; AND THE OPTIMS STUDY GROUP | |
| Increasing dose of ifn beta 1b in ms patients: preliminary nab results from the optims study. | 2003 | VERDUN E; A. RICCI; P. BARBERO; M. CLERICO; A. PIPIERI; M. BERGUI; E. VERSINO; A. CUCCI; J.J. ZHONG; L. DURELLI; AND OPTIMS STUDY GROUP | |
| Indicators of treatment response to interferon beta in ms. mxa protein, il-10 mrna or mri? | 2006 | G. CONTESSA; M. CLERICO; P. BARBERO; B. FERRERO; A. CUCCI; E. VERSINO; G. GIULIANI; E. MONTANARI; L. DURELLI; THE OPTIMS STUDY GROUP |